Abstract
David Anderson is a General Partner at Ampersand Capital Partners, Boston, MA. David joined Ampersand in 2010 and participates across many sectors in healthcare but with a special focus on CDMOs and biopharma services in the cell and gene therapy arena. David’s current and past board seats include Accuratus, BioClinica, Arranta Bio, Brammer Bio, Elite One Source, Stage Bio, Cellero, Vibalogics, and Genezen. David holds a BSc from the University of Aberdeen, Scotland, a PhD in Cancer Immunology from the University of Sheffield, England and an MBA from Babson College, MA.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
